On September 4, 2025, the Office of Information and Regulatory Affairs (OIRA) released the Spring 2025 Unified Agenda of Regulatory and Deregulatory Actions, outlining federal agencies’ intended regulatory activities over […]
Canada’s Chemicals Management Plan (CMP) program is sharing the following Risk Assessment Publication Plan to inform stakeholders of upcoming publications. The targeted publication dates are subject to change. The program […]
Health Canada has updated the 2022 version of the Guidance on management of drug submissions and applications. The changes to the guidance take effect immediately and will ensure that information […]
Health Canada is seeking feedback on proposed revisions to the Questions and Answers: Plain Language Labelling for Prescription Drugs Guidance Document. Revisions to the current guidance document have been […]
The updated monographs, published on September 26, 2025, primarily focuses on safety revisions related to the potential risk of hepatotoxicity from certain natural health products. Specifically, monographs for Turmeric/curcuminoids […]
The Natural and Nonprescription Health Products Directorate (NNHPD) held two “What we Heard” sessions on NHP MAP Wave 1 and the Two New Tools. A summary of what […]
The Natural & Non-prescription Health Products Directorate (NNHPD) has updated entries in the NHPID for several ingredients used in NHPs and NPDs. In February 2025 the entries for […]
PRODUCT LICENSING: The NNHPD has returned to meeting its performance standards for new and post-licensing Class I and II applications. There are approximately 4150 files in Class III […]
Cosmetics Alliance recently sent a letter to Prime Minister Mark Carney in August, in advance of the announcement of the Red Tape Reduction initiative. The letter outlined 5 proposed actions […]
IFRA has finalized its decision to classify Diphenyl Oxide (DPO) as a Category 1B reproductive toxicant. This classification is based on data from the ECHA (European Chemicals Agency) and […]
